Romanian Deputy PM Resigns Over Old Bribery Case
Anastasiu had been tasked by Prime Minister Ilie Bolojan with overseeing the reform of state-owned companies as part of the coalition government's push to reduce the largest budget deficit in the European Union. The deficit sat at 9.3 percent in 2024, according to S&P Global.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Palantir, AMD, Disney: Earnings to watch this week
Asking for a Trend host Josh Lipton goes over the biggest earnings reports to keep an eye on during the week of Monday, Aug. 4. Palantir (PLTR) will report its second quarter results after markets close on Monday. Investors expect good results from the company's commercial segment. Advanced Micro Devices (AMD) will release its second quarter results after markets close on Tuesday. Investors will be looking at GPU sales, artificial intelligence (AI) revenue, and plans for further growth in the second half of the year. Disney (DIS) will post its results before markets open on Wednesday. Investors anticipate a solid report likely unaffected by competitors and will be looking for updates on the company's growth in the streaming space. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend. Well, time now for to watch and earnings coming up. Palantir, AMD, and Disney. Start with Palantir, which is reporting second quarter earnings after the bell on Monday. Company stock has shot up over 100% year to date marking the company as one of the best performing stocks in the S&P 500. Investors expecting good results for Palantir's commercial segment. They're aware of pressures like potential competition and defense contracts and other AI giants. And next up, we got AMD. It's set to release its second quarter results after the bell Tuesday. The semiconductor manufacturers stock has rallied massively throughout the quarter spurred on by the booming AI trade as well as momentum in the company's PC business. As a result, investors expecting solid future results with more emphasis in GPU sales, AI revenue, and preparations to grow the company in the second half of 2025. And finally, talk about Disney, which reports earnings before the bell on Wednesday. Analysts saying that the media giant will have a solid third quarter likely unaffected by competitors attempting to break into the theme park space like Comcast's Epic Univers Universe. Investors watching for updates on the media giant's growth in the streaming arena. Related Videos Bad news flurry, IPO market, crypto dive: Market takeaways Earnings, Fed commentary, consumer credit: What to Watch IPO market heats up: These 4 names prepare to go public next Berkshire Hathaway earnings: 'Perfect' stock to own when 'worried' Effettua l'accesso per consultare il tuo portafoglio
CNN
an hour ago
- CNN
European plans to send asylum seekers to offshore centers in disarray after top court ruling
Immigration European UnionFacebookTweetLink Follow European countries hoping to mirror Italy's controversial practice of sending some asylum seekers rescued at sea to overseas deportation centers have been dealt a setback by Europe's top court. On Friday, the European Court of Justice (ECJ) ruled that while Italy could still utilize the centers it runs in the Albanian cities of Shengiin and Gjader, who can be sent there must be more closely examined to ensure that asylum seekers aren't being sent back to dangerous situations in their home countries. The court said that a country of origin can only be considered 'safe' after it has been 'subject to effective judicial review,' and that a country must be demonstrably safe for all its population, including vulnerable or marginalized groups. The ECJ ruling will almost certainly impact new EU asylum regulations, which are set to take effect next June and are designed to allow member states to create their own 'safe' country lists to expedite and outsource the asylum process. The EU's own list, meant to be a guide, includes Bangladesh, Columbia, Egypt, India, Kosovo, Morocco and Tunisia, despite human rights campaigners warning that those countries aren't safe for all who live there. 'The proposed EU list of 'safe countries of origin' deems certain countries, from which 20% or fewer applicants are granted international protection in the EU, to be safe,' Amnesty International said in a July statement. 'However, the fact that up to 20% of those applying for international protection from these countries are recognized as refugees indicates that these places are in fact not safe for all,' it added. The ECJ ruling – which was based on two Bangladeshi asylum seekers who were detained in Albania but argued returning to Bangladesh was unsafe – comes as several European countries have expressed interest in developing their own deportation schemes like the Italian-Albanian partnership. While that partnership, a multi-million-euro investment of detention centers and 'return hubs' in a non-EU country, has been viewed by some countries as a potential blueprint for success, a recent study by the University of Bari found that the Italian scheme has, so far, cost the country more than €74.2 million (approximately $86 million). The study called the scheme 'the most costly, inhumane, and useless instrument in the history of Italian migration policies.' Still, European Commission president Ursula von der Leyen and then European Council president Charles Michel lauded Italy's 2023 landmark agreement, and in May 2024, the EU established a set of reforms designed to streamline Europe's approach to managing migration and asylum, particularly around migrants from so-called 'safe' countries. Calling it 'fair but firm,' the pact lays out wide-ranging reforms designed to ease the burden on countries that have historically taken the most asylum-seekers among the EU's 27 member states. Whether this ECJ ruling will dissuade the development of the detentions hubs remains to be seen. Italy's far-right Prime Minister Giorgia Meloni criticized the court's decision as short sighted, saying that it 'weakens policies to combat mass illegal immigration and protect national borders.' 'This is a development that should concern everyone – including the political forces rejoicing today over the ruling – because it further reduces the already limited scope for governments and parliaments to regulate and administer migration,' she said. Meanwhile, in Italy's detention centers in Albania, the lives of nearly a dozen people from countries deemed safe, including Egypt and Bangladesh, hang in the balance.
Yahoo
2 hours ago
- Yahoo
Oppenheimer Predicts Up to 590% Rally for These 2 ‘Strong Buy' Stocks
There's a lot to say about the economy and markets today. Earnings season is well underway, with 317 S&P 500 companies having reported so far, and the results have been broadly encouraging – 83% have topped profit forecasts. That strength has helped drive both the S&P 500 and NASDAQ toward record highs, although August began with a pullback as investors reacted to a weaker-than-expected jobs report and the rollout of new tariffs from President Trump. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Even with those headwinds, Oppenheimer's chief investment strategist John Stoltzfus remains optimistic about the path ahead. 'This year reminds us of the classic Charles Dickens quote, 'It was the best of times, it was the worst of times.' Although much uncertainty and worry prevailed for some time both with trade policy and geopolitical events, and given the multitude of potential outcomes, we'd note that cooler heads prevailed – leading to positive outcomes at least for now. Monetary policy by the Fed has brought down the pace of inflation (if not yet to its 2% target level) without thus far causing a recession. This in our view is a substantial achievement… We are revising our year-end price target for the S&P 500 to 7,100 from 5,950,' Stoltzfus noted. That S&P target implies a gain of ~14% from current levels, a solid gain by any standard. But some stocks are going to outperform, even substantially – and Oppenheimer analysts are predicting much stronger rallies for 2 names in particular, including one with a potential upside as high as 590%. Using the TipRanks database, we've looked at the big-picture view on both of these picks, and it seems the broader Street agrees with Oppenheimer's bullish stance – both stocks hold Strong Buy consensus ratings, with forecasts pointing to potential triple-digit gains. Let's dig into what makes these high-upside picks so compelling. Climb Bio (CLYM) We'll start with Climb Bio, a biotech research firm focused on developing new treatments for immune-mediated diseases. These conditions – affecting an estimated 1 in 7 people worldwide – often stem from malfunctioning B cells, which can mistakenly attack the body's own tissues. Climb is developing therapies that target this root cause, aiming to address a range of serious and underserved diseases. The company's pipeline includes two drug candidates: its lead program, budoprutug, is currently being tested in three clinical trials and one preclinical study, while its second candidate, CLYM116, remains in preclinical development. Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B cells. The drug has shown encouraging early clinical data and is now being evaluated in clinical trials across three distinct indications: primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). In pMN, a rare autoimmune kidney disorder that causes damaging protein leakage into the urine, budoprutug is entering a Phase 2 open-label, dose-ranging trial to assess safety and efficacy. This follows positive data from a small Phase 1b study, in which 3 of 5 patients who completed all four doses achieved complete remission of proteinuria. All five patients in that study experienced rapid and sustained B-cell depletion, even at the lowest tested dose of 100 mg, and no serious drug-related adverse events were reported. Meanwhile, in ITP, Climb has received FDA clearance to begin a Phase 1b/2a study, with the trial now advancing. ITP is an autoimmune disorder in which B cells produce antibodies that target and destroy platelets. Budoprutug is being tested in this setting based on its CD19-targeting mechanism, which may offer an advantage over CD20-based therapies by depleting a broader range of B-cell populations, including plasma cells that drive the underlying disease process. The drug is also being explored in SLE, a chronic autoimmune disease that can cause widespread inflammation and tissue damage across multiple organs. A Phase 1b trial has been cleared by the FDA and is set to run at ex-U.S. sites. This open-label study is designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of clinical efficacy. Climb's B-cell-targeted approach is supported by the well-established role these cells play in driving lupus pathogenesis. To further expand its reach, Climb is also developing a subcutaneous formulation of budoprutug, with a Phase 1 trial in healthy volunteers expected to begin by year-end. Beyond budoprutug, Climb is advancing its second candidate, CLYM116, an Fc-engineered anti-APRIL monoclonal antibody with a novel pH-dependent mechanism. Currently in preclinical development, CLYM116 is being explored as a treatment for IgA nephropathy (IgAN), a serious kidney disorder also known as Berger's disease. Climb expects to report preclinical data and submit an Investigational New Drug (IND) application or Clinical Trial Application (CTA) by year-end. With CLYM trading at $1.45, Oppenheimer analyst Leland Gershell views the stock as a high-potential opportunity, pointing to the company's advancing clinical pipeline and the therapeutic promise of budoprutug. 'We have a favorable outlook on budoprutug across its three indications in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE)… Each of these indications has clear IgG-driven pathophysiology and significant residual unmet need, despite existing first- and second-line therapies, where budoprutug has opportunity to shine above… We see $1B+ sales potential across these indications, and a subcutaneous, potentially use-at-home version offers upside optionality… With shares reflecting little credit for the company's opportunities and cash runway into 2027, we see favorable risk-reward and encourage investors to build a position. We would expect positive results in pMN to generate considerable stock upside potential,' Gershell opined. So how much upside does Gershell see overall? The analyst rates CLYM an Outperform (i.e., Buy), with a $10 price target – implying a substantial 590% surge over the next year. (To watch Gershell's track record, click here) Supporting this optimistic outlook, CLYM has 3 recent analyst reviews on record – all unanimously positive – earning the stock a Strong Buy consensus rating. With an average price target of $9, analysts expect shares to be changing hands at ~521% premium over the next 12 months. (See CLYM stock forecast) Wave Life Sciences (WVE) The next Oppenheimer pick is Wave Life Sciences, a biotech company developing a lineup of RNA medicines through its proprietary platform, dubbed PRISM. RNA therapeutics represent a fast-growing frontier in biotechnology, and Wave is harnessing innovations in chemistry and human genetics to create targeted treatments for serious, genetically driven diseases that have historically lacked effective solutions. This ambitious vision is translating into a diverse clinical pipeline. Wave is advancing four distinct programs, each built on a separate RNA modality: WVE-006 uses RNA editing, WVE-007 employs RNA interference (RNAi), WVE-N531 leverages exon skipping, and WVE-003 utilizes allele-selective silencing. By tackling different mechanisms and indications, the company is positioning itself to address multiple areas of high unmet medical need. WVE-006 is a GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide (AIMer) designed to treat alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver. The drug is currently in the Phase 1b/2a RestorAATion-2 trial, with key clinical data from both the 200 mg single and multidose cohorts expected in the third quarter of 2025. Additional results from the 400 mg single-dose cohort are anticipated later this fall. Progress is also accelerating with WVE-007, an RNAi therapy targeting obesity. This GalNAc-siRNA candidate works by silencing the INHBE gene and has shown strong preclinical efficacy in reducing weight while preserving muscle mass. Following promising initial safety and pharmacodynamic results in Cohort 1, Wave expanded enrollment in Cohort 2 and expects data from the first two cohorts in Q4 2025, with high-dose cohort results to follow in early 2026. The third program, WVE-N531, is an exon-skipping oligonucleotide developed for Duchenne muscular dystrophy (DMD), a severe and progressive neuromuscular disorder. In a Phase 2 open-label trial, the therapy showed statistically significant and clinically meaningful improvements in Time-to-Rise, a key measure of functional strength. Wave plans to submit a New Drug Application (NDA) in 2026 to pursue accelerated approval. Rounding out the clinical pipeline is WVE-003, an allele-selective oligonucleotide designed for Huntington's disease (HD). This first-in-class candidate has demonstrated selective reduction of mutant huntingtin protein (mHTT) while preserving healthy wild-type HTT – an approach believed to protect neuronal function. A Phase 2/3 trial is in planning, with Wave aiming to submit an IND in the second half of 2025. This pipeline, and its potential for success, has caught the attention of Oppenheimer analyst Cheng Li, who writes: 'We think RNA medicine is poised to become an important therapeutic modality for future medicine, leveraging its unique target engagement mechanism compared to other modalities. The PRISM platform further enhances the potency, durability, tissue distribution, and pharmacological properties of oligonucleotides in a multimodal fashion… We are optimistic about WVE's four clinical programs, each having its own merits and collectively providing validation to the platform technology that propels a next wave of programs for high-value targets with differentiated approaches… We anticipate multiple meaningful clinical catalysts from WVE-006 for alpha1 antitrypsin deficiency (AATD) and WVE-007 for obesity, with current valuation offering a favorable risk/reward setup.' Reflecting this conviction, Li assigns WVE an Outperform (i.e., Buy) rating, along with a $24 price target that suggests shares could surge 178% over the next year. (To watch Li's track record, click here) Li's bullish stance is echoed across the Street. The stock has picked up 12 recent analyst reviews, supporting a Strong Buy consensus rating, with an 11-to-1 split favoring Buys over Holds. Shares currently trade at $8.63, and the average price target of $18.18 points to a potential upside of ~111% over the next 12 months. (See WVE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
